Victory Capital Management
RCUS icon

Victory Capital Management’s Arcus Biosciences RCUS Stock Holding History

Victory Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$292K Buy
13,513
+1,213
+10% +$26.2K ﹤0.01% 2128
2025
Q4 		$293K Buy
12,300
+1,610
+15% +$32.8K ﹤0.01% 2118
2025
Q3 		$145K Sell
10,690
-796
-7% -$8.28K ﹤0.01% 2256
2025
Q2 		$93.5K Sell
11,486
-50,854
-82% -$434K ﹤0.01% 2332
2025
Q1 		$489K Buy
62,340
+16,622
+36% +$193K ﹤0.01% 2038
2024
Q4 		$681K Sell
45,718
-2,764
-6% -$45.1K ﹤0.01% 1947
2024
Q3 		$741K Sell
48,482
-1,220
-2% -$19.2K ﹤0.01% 1894
2024
Q2 		$757K Sell
49,702
-25,624
-34% -$414K ﹤0.01% 1826
2024
Q1 		$1.42M Sell
75,326
-29,087
-28% -$503K ﹤0.01% 1573
2023
Q4 		$1.99M Buy
104,413
+36,312
+53% +$580K ﹤0.01% 1429
2023
Q3 		$1.22M Sell
68,101
-6,062
-8% -$122K ﹤0.01% 1559
2023
Q2 		$1.51M Sell
74,163
-19,903
-21% -$379K ﹤0.01% 1492
2023
Q1 		$1.72M Buy
94,066
+28,403
+43% +$543K ﹤0.01% 1452
2022
Q4 		$1.36M Buy
65,663
+48,003
+272% +$1.32M ﹤0.01% 1581
2022
Q3 		$462K Buy
17,660
+1,898
+12% +$50.2K ﹤0.01% 2082
2022
Q2 		$399K Sell
15,762
-1,469
-9% -$36K ﹤0.01% 2149
2022
Q1 		$417K Buy
17,231
+10,384
+152% +$348K ﹤0.01% 2191
2021
Q4 		$277K Sell
6,847
-436
-6% -$16.9K ﹤0.01% 2404
2021
Q3 		$254K Sell
7,283
-63,577
-90% -$1.98M ﹤0.01% 2438
2021
Q2 		$1.95M Sell
70,860
-1,459,488
-95% -$41.7M ﹤0.01% 1645
2021
Q1 		$43M Buy
1,530,348
+397,786
+35% +$13.8M 0.04% 611
2020
Q4 		$29.4M Sell
1,132,562
-55,997
-5% -$1.36M 0.03% 722
2020
Q3 		$20.4M Buy
1,188,559
+295,955
+33% +$6.61M 0.03% 791
2020
Q2 		$22.1M Buy
892,604
+882,912
+9,110% +$23.8M 0.03% 732
2020
Q1 		$134K Buy
+9,692
New +$121K ﹤0.01% 2445
2019
Q4 		– Sell
-4,491
Closed -$41K – 3131
2019
Q3 		$41K Buy
+4,491
New +$36.1K ﹤0.01% 2769

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Victory Capital Management's RCUS Position: Q1 2026 in Review

Victory Capital Management increased its Arcus Biosciences (RCUS) stake by 9.9% in Q1 2026, buying an estimated $26.2K and bringing the position to 13,513 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #2128.

Victory Capital Management first reported a position in RCUS in Q3 2019 and has held it in 26 quarters since. The position peaked at $43M in Q1 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Victory Capital Management held 13,513 shares of Arcus Biosciences worth $292K as of Q1 2026.
  • Victory Capital Management bought 1,213 Arcus Biosciences shares in Q1 2026, an estimated $26.2K.
  • Arcus Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2128 holding.
  • Victory Capital Management first reported a position in Arcus Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Victory Capital Management's Arcus Biosciences position peaked at $43M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.